Paw Incision Model Development Service
Post-surgical pain remains a significant challenge in healthcare, impacting patient recovery, quality of life, and healthcare costs. Are you currently facing challenges in accurately modeling post-surgical pain for novel analgesic development, leading to prolonged drug discovery cycles? Our paw incision model development service helps you accelerate drug discovery and obtain high-quality, translatable preclinical data through advanced, standardized surgical techniques and comprehensive behavioral assessments.
The paw incision model development service at Creative Biolabs provides a robust platform for investigating post-operative pain. This service is built upon the foundational work by Brennan and colleagues, who established the initial rat model, and subsequent adaptations for mice by Pogatzki–Zahn and Raja. These models are widely recognized for their ability to reliably induce and characterize acute inflammatory and neuropathic pain components, mirroring human post-surgical conditions. Our expertise ensures these clinically relevant models support your research with high fidelity.
How Our Paw Incision Model Development Service Can Assist Your Project
CBL's paw incision model development service delivers precise, reproducible, and clinically relevant data to advance your analgesic development programs. You can expect meticulously executed studies, comprehensive pain phenotyping, and detailed mechanistic insights, all tailored to your specific research objectives. Our service ensures that your preclinical findings are robust and translatable, supporting confident decision-making in your drug discovery pipeline.
Discover How We Can Help - Request a Consultation
Workflow
Our workflow for the paw incision model development service is designed for clarity, efficiency, and scientific rigor, ensuring seamless project execution from initiation to final data delivery.
-
Required Starting Materials: To initiate your project, clients typically provide:
- Detailed Study Protocol: Including specific research questions, desired animal strains, and any preliminary data.
- Compound Information: Details on test compounds, including desired dosing regimens, routes of administration, and stability data.
- Ethical Approvals: Confirmation of relevant institutional animal care and use committee (IACUC) approvals or guidance on obtaining them.
-
Final Deliverables: Upon project completion, you will receive:
- Comprehensive Study Report: A detailed document outlining all experimental procedures, raw data, statistical analyses, and conclusions.
- Raw Data Files: All original data files from behavioral assessments and any other assays performed.
- Presentation of Key Findings: A summary presentation highlighting the most critical results and their implications, often delivered in a collaborative discussion.
- Estimated Timeframe: The typical timeframe for a paw incision model development service project ranges from 8 to 16 weeks, depending on the complexity of the study design, the number of experimental groups, and the duration of post-surgical observation periods. Factors such as compound availability and specific assessment requirements can influence the overall timeline.
Why Choose Us?
Choosing CBL for your paw incision model development service means partnering with a leader in preclinical pain research, committed to delivering exceptional scientific outcomes. Our unparalleled expertise, state-of-the-art facilities, and collaborative approach set us apart. We don't just provide data; we provide insights that drive your drug discovery forward.
Experience the Advantage - Get a Quote Today
Customer Reviews
"Robust Data. Using CBL's paw incision model development service in our research has significantly improved the reliability and translatability of our analgesic efficacy studies. Their meticulous surgical technique and comprehensive behavioral assessments provided data we could truly trust, allowing us to confidently down-select our lead compounds." - Dr. J*ne D*e, Research Scientist
"Streamlined Process. CBL's expertise in the paw incision model greatly facilitated our investigation into stress-induced pain exacerbation. Their ability to integrate acute and chronic stress paradigms into the model was invaluable, providing deeper mechanistic insights than we could achieve internally. The detailed reports were incredibly helpful for our grant applications." - Dr. M*rk S*th, Principal Investigator
"Exceptional Support. We faced challenges with reproducibility in our in-house pain models. CBL's paw incision model development service offered a level of standardization and consistency that transformed our research. Their team's responsiveness and scientific guidance throughout the project were outstanding, making them a true partner in our drug development efforts." - Dr. A*na K*ur, Senior Biologist
Paw Incision Model
The paw incision model stands as a cornerstone in preclinical pain research, recognized globally for its ability to reliably induce and characterize post-operative pain. Originally described by Brennan and colleagues and later adapted for mice by Pogatzki–Zahn and Raja, this model accurately replicates the acute inflammatory and neuropathic components of post-surgical pain experienced by patients. It involves a controlled incision on the plantar surface of the hind paw, leading to predictable and quantifiable pain behaviors. This widely adopted model is a testament to its reliability and clinical relevance across various research institutions.
The efficacy of the paw incision model lies in its:
- Clinical Relevance: It closely mimics the tissue injury and subsequent pain pathways activated during human surgical procedures, making it highly translatable.
- Reliability and Reproducibility: Standardized surgical techniques and behavioral assessments ensure consistent and reproducible results, crucial for robust data generation.
- Comprehensive Pain Assessment: The model allows for the evaluation of various pain modalities, including mechanical, thermal, and cold hypersensitivity, providing a holistic view of the pain experience.
What We Can Offer
At CBL, our paw incision model development service is meticulously designed to meet the diverse and evolving needs of biology experts like you. We combine scientific rigor with a client-centric approach to deliver superior results.
- Customized Study Design: We provide highly flexible and customized study designs, adapting the Paw Incision Model to precisely fit your unique research questions, compound profiles, and desired outcomes, ensuring optimal experimental relevance.
- Comprehensive Preclinical Pain Assessment: Benefit from our one-stop solution for robust behavioral phenotyping, including mechanical, thermal, and cold hypersensitivity, coupled with advanced mechanistic analyses such as histology, IHC, and biomarker quantification.
- Expert Surgical Precision: Our highly skilled surgical team employs standardized, reproducible techniques, ensuring consistent incision parameters and minimizing variability for reliable data generation, critical for the integrity of your research.
- Integrated Modulating Factors: Leverage our unique capability to integrate physiological and psychological modulating factors, such as acute or chronic stress paradigms, to explore complex pain mechanisms and identify novel therapeutic targets with greater translational potential.
- Rigorous Quality Control: Our well-established quality system, incorporating meticulous aseptic verification procedures and high-standard quality control tools, guarantees the accuracy, reliability, and integrity of all data generated from your Paw Incision Model studies.
- Dedicated Scientific Partnership: From initial consultation to final data interpretation, our team of experienced biologists and pain specialists acts as an extension of your research team, providing continuous scientific guidance and ensuring a collaborative and transparent project experience.
Related Services
To further support your comprehensive pain research and drug discovery initiatives, CBL offers a range of complementary services and model variations:
- Acute Pain Models
- Inflammatory Pain Models
- Biomarker Development & Validation
- Neuroinflammation Studies
Ready to accelerate your pain research? Our expert team is here to discuss your specific project needs and provide tailored solutions.
Contact Our Team for More Information and to Discuss Your Project.
- iNeuMab™ Mouse Anti-SHANK3 Monoclonal Antibody (CBP929) (Cat#: NAB-0720-Z3477)
- iNeuMab™ Rabbit Anti-Alpha-synuclein (CBP1631) (Cat#: NAB-08-PZ079)
- iNeuMab™ Mouse Anti-EFNB2 Monoclonal Antibody (CBP1159) (Cat#: NAB-0720-Z4396)
- iNeuMab™ Anti-F-Spondin/SPON1 Antibody, Clone 3F4 (Cat#: NRZP-0822-ZP4740)
- Mouse Anti-SCN5A Monoclonal Antibody (CBP708) (Cat#: NAB-0720-Z2720)
- iNeuMab™ Rabbit Anti-LRRK2 Monoclonal Antibody (CBP1887) (Cat#: NAB-08-PZ735)
- Mouse Anti-Human α-Synuclein Phospho (Tyr39) (CBP3706) (Cat#: NAB201250LS)
- iNeuMab™ Mouse Anti-LRP1 Monoclonal Antibody (CBP3363) (Cat#: NAB-0720-Z6479)
- Mouse Microglia from C57BL/6 (Cat#: NCL-21P6-082)
- Human Brain Microvascular Endothelial Cells (Cat#: NCL-2103-P133)
- iNeu™ Human Schwann Cell (Cat#: NCL-2103-P63)
- Mouse Retinal Ganglion Cells (Cat#: NCL2110P145)
- Rat Microglia Cell Line HAPI, Immortalized (Cat#: NCL2110P015)
- Human Brain Astroblastoma U-87 MG (Cat#: NCL2110P117)
- iNeu™ Human Sensory Neurons (Cat#: NCL-2103-P62)
- Rat Schwann Cells RSC96, Immortalized (Cat#: NCL-2108P21)
- Mouse Glioma Cell Line GL261-GFP (Cat#: NCL-2108P04)
- Green Fluorescent BACE1 Cell Lines (Cat#: NCL2110P214)
- Amyloid beta 1-42 Kit (Cat#: NRP-0322-P2170)
- Human GFAP ELISA Kit [Colorimetric] (Cat#: NPP2011ZP383)
- Alpha-Synuclein Aggregation Assay Kit (Cat#: NRZP-1122-ZP37)
- Beta Amyloid (1-42), Aggregation Kit (Cat#: NRZP-0323-ZP200)
- Human Tau Aggregation Kit (Cat#: NRP-0322-P2173)
- Alpha Synuclein Aggregation Kit (Cat#: NRZP-1122-ZP15)
- Human Poly ADP ribose polymerase,PARP Assay Kit (Cat#: NRZP-1122-ZP62)
- Beta Amyloid (1-40), Aggregation Kit (Cat#: NRZP-0323-ZP199)
- Dextran, NHS Activated (Cat#: NRZP-0722-ZP124)
- VSV-eGFP (Cat#: NTA-2011-ZP20)
- AAV2 Full Capsids, Reference Standards (Cat#: NTC2101070CR)
- Mouse SOD1 shRNA Silencing Adenovirus (Cat#: NV-2106-P14)
- Human huntingtin (HTT) (NM_002111) ORF clone, Myc-DDK Tagged (Cat#: NEP-0521-R0497)
- Human superoxide dismutase 3, extracellular (SOD3) (NM_003102) ORF clone, Untagged (Cat#: NEP-0521-R0808)
- ABCA1 Antisense Oligonucleotide (NV-2106-P27) (Cat#: NV-2106-P27)
- Lenti of Human TAR DNA binding protein (TARDBP) (NM_007375) ORF clone, mGFP Tagged (Cat#: NEP-0521-R0832)
- Lenti of Mouse synuclein, alpha (Snca) transcript variant (NM_001042451) ORF clone, mGFP Tagged (Cat#: NEP-0521-R0864)
- Human presenilin 1 (PSEN1), transcript variant 2 (NM_007318) ORF clone, TurboGFP Tagged (Cat#: NEP-0421-R0140)
- Tau Antisense Oligonucleotide (IONIS-MAPTRx) (Cat#: NV-2106-P29)
- App Rat amyloid beta (A4) precursor protein (App)(NM_019288) ORF clone, Untagged (Cat#: NEP-0421-R0053)
- Human huntingtin-associated protein 1 (HAP1) transcript variant 2 (NM_177977) ORF clone, Myc-DDK Tagged (Cat#: NEP-0521-R0676)
- NeuroBiologics™ Pig Cerebrospinal Fluid (Cat#: NRZP-0822-ZP498)
- NeuroBiologics™ Mouse Cerebrospinal Fluid (Cat#: NRZP-0822-ZP497)
- NeuroBiologics™ Human Cerebrospinal Fluid (Cat#: NRZP-0822-ZP491)
- NeuroBiologics™ Monkey Cerebrospinal Fluid (Cat#: NRZP-0822-ZP495)
- NeuroBiologics™ Rat Cerebrospinal Fluid (Cat#: NRZP-0822-ZP496)
- NeuroPro™ Anti-TNFR BBB Shuttle Protein (Cat#: NRZP-0423-ZP501)
- NeuroPro™ Anti-ASA BBB Shuttle Protein (Cat#: NRZP-0423-ZP504)
- NeuroPro™ Anti-PON1 BBB Shuttle Protein (Cat#: NRZP-0423-ZP507)
- NeuroPro™ Anti-IDUA BBB Shuttle Protein (Cat#: NRZP-0423-ZP502)
- NeuroPro™ Anti-GDNF BBB Shuttle Protein (Cat#: NRZP-0423-ZP500)
- NeuroPro™ Anti-TNFR BBB Shuttle Protein (Cat#: NRZP-0423-ZP510)
- NeuroPro™ Anti-SGSH BBB Shuttle Protein (Cat#: NRZP-0423-ZP505)
- NeuroPro™ Anti-idursulfase BBB Shuttle Protein (Cat#: NRZP-0423-ZP497)
- NeuroPro™ Anti-IDUA BBB Shuttle Protein (Cat#: NRZP-0423-ZP498)
- NeuroPro™ Anti-Erythropoietin BBB Shuttle Protein (Cat#: NRZP-0423-ZP499)